MitraClip Guidelines: Patient Selection and Post-Procedure Management
MitraClip (transcatheter edge-to-edge repair) is indicated for severely symptomatic patients with primary mitral regurgitation at prohibitive surgical risk, and for carefully selected patients with secondary mitral regurgitation who remain symptomatic despite optimized guideline-directed medical therapy. 1
Patient Selection Criteria
Primary (Degenerative) Mitral Regurgitation
For primary MR, MitraClip is approved for patients who are at prohibitive surgical risk as determined by a multidisciplinary heart team 2. The 2020 ACC/AHA guidelines give this a Class IIb recommendation for severely symptomatic patients (NYHA class III-IV) with chronic severe primary MR who have favorable anatomy but prohibitive surgical risk 3.
Key anatomical requirements for optimal outcomes:
- Grasping zone ≥10 mm without calcification
- Flail width <15 mm
- Flail gap <10 mm
- Single middle segment prolapse preferred
- Mitral valve area ≥4.0 cm² to exclude stenosis
- Mean transmitral gradient <5 mm Hg 4
Secondary (Functional) Mitral Regurgitation
This is where the guidelines have evolved most significantly. The 2020 ACC/AHA guidelines state that mitral transcatheter edge-to-edge repair benefits a select subset of patients with secondary MR who remain severely symptomatic despite guideline-directed management and therapy for heart failure 1.
Mandatory prerequisites before considering MitraClip:
- Optimization of GDMT is required first - this includes ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists, and SGLT2 inhibitors 5, 1
- Cardiac resynchronization therapy (CRT) when indicated 4
- Revascularization if ischemic etiology 5
- Reassess MR severity after optimization - many patients improve with medical therapy alone 6
Specific anatomical and clinical criteria for secondary MR (based on COAPT trial parameters):
- LVEF between 20-50%
- Left ventricular end-systolic diameter ≤70 mm
- Pulmonary artery systolic pressure ≤70 mm Hg
- Grasping zone ≥10 mm without calcification
- Persistent severe MR despite optimal medical therapy
- NYHA class II-IV symptoms 7, 4
Critical distinction: The benefit of MitraClip in secondary MR depends on the degree of MR relative to LV remodeling. Patients with "disproportionate MR" (MR out of proportion to LV remodeling) respond better to MitraClip than those with "proportionate MR" 7.
Multidisciplinary Heart Team Evaluation
All patients must be evaluated by a multidisciplinary heart team that includes:
- Cardiac surgeon
- Interventional cardiologist
- Heart failure cardiologist
- Imaging cardiologist
- Additional specialists as needed (pulmonologist, nephrologist, hepatologist, geriatrician) 2, 1, 2
The heart team must reach consensus that the patient is not appropriate for surgical mitral valve repair/replacement 2, 8.
Post-Procedure Management
Immediate Post-Procedure Care
Anticoagulation/Antiplatelet Therapy:
For patients in sinus rhythm:
- Dual antiplatelet therapy (aspirin + clopidogrel) for 4 weeks
- Followed by aspirin monotherapy indefinitely 9
For patients with atrial fibrillation:
- Lifelong oral anticoagulation (warfarin or NOAC based on CHA2DS2-VASc score)
- Combined with single antiplatelet agent for 4 weeks 9
Endocarditis Prophylaxis
Endocarditis prophylaxis is indicated for at least 6 months post-procedure 9. This is a critical point often overlooked.
Cardiac Rehabilitation
Rehabilitation is indicated after MitraClip due to underlying heart failure:
- Optimization of GDMT (ACE inhibitors, beta-blockers, aldosterone antagonists)
- Standardized heart failure training programs
- Strength and endurance training
- Psychosocial support 9
Echocardiographic Surveillance
Key parameters to monitor on follow-up echocardiography:
- Residual atrial septal defect (from transseptal puncture)
- Transmitral gradient (to detect iatrogenic mitral stenosis)
- Residual mitral regurgitation severity
- Left ventricular function and remodeling 9
Follow-up schedule: Echocardiography should be performed during rehabilitation, at routine cardiology visits, and whenever clinical status changes 9.
Long-Term Outcomes and Monitoring
Expected outcomes based on registry data:
- Procedural mortality: 2-3%
- 30-day mortality: 1.8-7.7% (varies by patient risk profile)
- 1-year mortality: 15-24% (reflects high-risk population)
- MR reduction to ≤2+ achieved in 78-92% at 1 year
- NYHA functional class improvement in 80% of patients 2, 8, 2
Patients with NT-proBNP >10,000 pg/mL have high mortality despite MitraClip and require very individualized decision-making 10. This represents end-stage heart failure where MitraClip may be futile.
Common Pitfalls to Avoid
Performing MitraClip before optimizing GDMT in secondary MR - this is the most common error. GDMT optimization can resolve severe MR in over 50% of patients 6.
Ignoring the proportionate vs. disproportionate MR distinction - proportionate MR responds better to therapies that reverse LV remodeling (GDMT, CRT) rather than MitraClip 7.
Inadequate anatomical assessment - severe mitral annular calcification, insufficient grasping zone, or unfavorable leaflet pathology predict poor outcomes 4.
Proceeding without heart team consensus - this is both a guideline requirement and improves patient selection 1, 2.
Forgetting endocarditis prophylaxis - required for at least 6 months 9.